Sort
51,593 grants matching “hepatitis”
Development of PAR2 Pepducins as a Novel NASH Treatment
$1,056,106Athan Kuliopulos · Oasis Pharmaceuticals · R44 · FY2019 · DK
Human Pancreas Analysis Program-T2D
$1,055,999Alvin Carter Powers · Vanderbilt University Medical Center · U01 · FY2024 · DK
Terry Beirn CPCRA Clinical Trials Unit
$1,055,836Fred M Gordin · George Washington University · UM1 · FY2015 · AI
Florida Node of The Drug Abuse Clinical Trials Network
$1,055,478Jose Szapocznik · University Of Miami School Of Medicine · U10 · FY2007 · DA
CELLULAR PATHOGENESIS OF PEDIATRIC LIVER DISEASE
$1,053,455Washington University · P01 · FY2000 · DK
Chicago Clinical Trials Unit
$1,053,181Chad J Achenbach · Northwestern University At Chicago · UM1 · FY2024 · AI
DIABETES PREVENTION PROGRAM (DPP)
$1,053,136Yeshiva University · U01 · FY2000 · DK
Phosphoinositide-calcium Signaling In Cell Regulation
$1,053,116Tamas Balla · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2016 · HD
Task 4: The Interventional Agent Development Services program
$1,052,978Norman Kneteman · Sri International · N01 · FY2013 · AI
Synthesis of Therapeutic Agents for Treatment of Infectious Diseases
$1,052,509Walter Powell · Starks Associates, Inc. · N01 · FY2010 · AI
Resource for NMR Molecular Imaging of Proteins
$1,052,237Stanley J Opella · University Of California, San Diego · P41 · FY2011 · EB
THE SOUTHEASTERN COOPERATIVE HEPATITIS C RESEARCH GROUP
$1,051,648University Of Texas Medical Br Galveston · U19 · FY2004 · AI
CIP Genomics Core
$1,051,527Colm Ohuigin · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Genetic Determinants of Antidepressant Response in the STAR*D Cohort
$1,051,501Francis J McMahon · National Institute Of Mental Health · ZIA · FY2010 · MH
ADULT THERAPEUTIC CLINICAL TRIALS PROGRAM IN AIDS
$1,051,286Beth Israel Medical Ctr (New York) · U01 · FY2001 · AI
Clinical Trials Units for NIAID Networks (UM1)
$1,051,232Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2017 · AI
RECOMBINANT AAV FOR CORRECTION OF GENETIC ABNORMALITIES
$1,051,117University Of Florida · P01 · FY2004 · DK
Project 3 - Flavivirus - UTMB
$1,050,868Pei-Yong Shi · University Of Alabama At Birmingham · U19 · FY2023 · AI
Transforming Clinical and Translational Research and Education at Rockefeller
$1,050,598Barry Coller · Rockefeller University · KL2 · FY2009 · RR
Human Polycystic Kidney Disease
$1,050,412University Of Colorado Denver · P01 · FY2004 · DK
Pathogenesis of Parenteral Viral Hepatitis
$1,050,189Robert H. Purcell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers
$1,050,159Frank J Gonzalez · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Development of PAR2 Pepducins as a Novel NASH Treatment
$1,048,644Athan Kuliopulos · Oasis Pharmaceuticals · R44 · FY2017 · DK
THE SOUTHEASTERN COOPERATIVE HEPATITIS C RESEARCH GROUP
$1,048,510University Of Texas Medical Br Galveston · U19 · FY2000 · AI
Johns Hopkins AIDS Clinical Trials Unit
$1,048,057Charles W. Flexner · Johns Hopkins University · U01 · FY2010 · AI